TickerFacts.

Castle Biosciences Inc (CSTL): Long-Term Debt

Annual figures by period end, from SEC filings.

$10.06M
As of 2025-12-31
$10.07M
As of 2026-06-30
$26.69M2019-12-31: $26.69M2023-12-31: $02024-12-31: $10.02M2025-12-31: $10.06M$10.06M
2019-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$10.06M+0.3%2026-02-26, Balance as of period end
2024-12-31$10.02Mn/a2026-02-26, Balance as of period end
2023-12-31$0n/a2025-02-27, Balance as of period end
No annual figure between 2019-12-31 and 2023-12-31.
2019-12-31$26.69Mn/a2020-03-10, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Castle Biosciences Inc (CSTL)2025-12-31$10.06M+0.3%
BillionToOne, Inc. (BLLN)2025-12-31$57.23M+11.2%
Caris Life Sciences, Inc. (CAI)2025-12-31$378.45M+1.4%
Guardant Health, Inc. (GH)2025-12-31$1.50B+31.6%
Biodesix Inc (BDSX)2025-12-31$50.01M+24.9%
Exagen Inc. (XGN)2025-12-31$22.91M+13.1%
RadNet, Inc. (RDNT)2025-12-31$1.09B+7.2%
American Shared Hospital Services (AMS)2025-12-31$17.40M-14.8%
Quest Diagnostics Inc (DGX)2025-12-31$5.67B-8.8%

Compare CSTL, BLLN, CAI, GH side by side · Screen every company in Services-Medical Laboratories ↗